183 related articles for article (PubMed ID: 17383421)
21. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
[TBL] [Abstract][Full Text] [Related]
22. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
[TBL] [Abstract][Full Text] [Related]
23. A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
You BC; Kim YS; Kim Hi; Kim SH; Park SS; Seo YR; Kim SG; Lee SW; Kim HS; Jeong SW; Jang JY; Kim BS
Clin Mol Hepatol; 2012 Sep; 18(3):272-8. PubMed ID: 23091807
[TBL] [Abstract][Full Text] [Related]
24. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
25. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
[TBL] [Abstract][Full Text] [Related]
26. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
Mejer N; Fahnøe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928732
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
28. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
[TBL] [Abstract][Full Text] [Related]
29. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
[TBL] [Abstract][Full Text] [Related]
31. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Symonds WT; Hindes RG; Berrey MM
N Engl J Med; 2013 Jan; 368(1):34-44. PubMed ID: 23281974
[TBL] [Abstract][Full Text] [Related]
32. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
[TBL] [Abstract][Full Text] [Related]
33. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
34. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.
Kanda T; Yokosuka O; Imazeki F; Tanaka M; Shino Y; Shimada H; Tomonaga T; Nomura F; Nagao K; Ochiai T; Saisho H
J Viral Hepat; 2004 Nov; 11(6):479-87. PubMed ID: 15500548
[TBL] [Abstract][Full Text] [Related]
36. Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
Chary A; Winters MA; Kottilil S; Murphy AA; Polis MA; Holodniy M
J Infect Dis; 2010 Sep; 202(6):889-93. PubMed ID: 20677940
[TBL] [Abstract][Full Text] [Related]
37. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
Di Marco V; Ferraro D; Almasio P; Vaccaro A; Parisi P; Cappello M; Cino N; Di Stefano R; Craxì A
J Viral Hepat; 2002 Sep; 9(5):354-9. PubMed ID: 12225330
[TBL] [Abstract][Full Text] [Related]
38. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
39. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
[TBL] [Abstract][Full Text] [Related]
40. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
